Supernus Pharmaceuticals annual gross margin
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Gross Margin Growth & History (SUPN)
Supernus Pharmaceuticals's gross margin was 89.63% for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 89.63% | +1.40 pp |
| 2024 | 2024-12-31 | 88.23% | +2.02 pp |
| 2023 | 2023-12-31 | 86.21% | −0.72 pp |
| 2022 | 2022-12-31 | 86.93% | −0.13 pp |
| 2021 | 2021-12-31 | 87.05% | −2.87 pp |
| 2020 | 2020-12-31 | 89.92% | −5.84 pp |
| 2019 | 2019-12-31 | 95.76% | −0.49 pp |
| 2018 | 2018-12-31 | 96.24% | +1.28 pp |
| 2017 | 2017-12-31 | 94.97% | +0.54 pp |
| 2016 | 2016-12-31 | 94.43% | +0.14 pp |
| 2015 | 2015-12-31 | 94.29% | +0.50 pp |
| 2014 | 2014-12-31 | 93.79% | +2.97 pp |
| 2013 | 2013-12-31 | 90.81% | — |
Supernus Pharmaceuticals quarterly gross margin
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 84.63% | −5.20 pp |
| Q1 2026 | 2026-03-31 | 88.74% | −0.74 pp |
| Q4 2025 | 2025-12-31 | 89.13% | +4.11 pp |
| Q3 2025 | 2025-09-30 | 90.13% | +0.14 pp |
| Q2 2025 | 2025-06-30 | 89.83% | +0.47 pp |
| Q1 2025 | 2025-03-31 | 89.48% | +0.83 pp |
| Q4 2024 | 2024-12-31 | 85.01% | −3.04 pp |
| Q3 2024 | 2024-09-30 | 89.99% | +2.73 pp |
| Q2 2024 | 2024-06-30 | 89.36% | +4.91 pp |
| Q1 2024 | 2024-03-31 | 88.65% | +3.90 pp |
| Q4 2023 | 2023-12-31 | 88.06% | +1.77 pp |
| Q3 2023 | 2023-09-30 | 87.26% | +1.85 pp |
| Q2 2023 | 2023-06-30 | 84.44% | −3.53 pp |
| Q1 2023 | 2023-03-31 | 84.74% | −3.50 pp |
| Q4 2022 | 2022-12-31 | 86.28% | −3.03 pp |
| Q3 2022 | 2022-09-30 | 85.41% | −2.41 pp |
| Q2 2022 | 2022-06-30 | 87.97% | +5.68 pp |
| Q1 2022 | 2022-03-31 | 88.24% | −0.34 pp |
| Q4 2021 | 2021-12-31 | 89.32% | +2.23 pp |
| Q3 2021 | 2021-09-30 | 87.82% | +1.61 pp |
| Q2 2021 | 2021-06-30 | 82.29% | −11.09 pp |
| Q1 2021 | 2021-03-31 | 88.58% | −7.05 pp |
| Q4 2020 | 2020-12-31 | 87.09% | −8.82 pp |
| Q3 2020 | 2020-09-30 | 86.21% | −9.07 pp |
| Q2 2020 | 2020-06-30 | 93.38% | −2.75 pp |
| Q1 2020 | 2020-03-31 | 95.63% | −0.06 pp |
| Q4 2019 | 2019-12-31 | 95.91% | −0.48 pp |
| Q3 2019 | 2019-09-30 | 95.28% | −0.63 pp |
| Q2 2019 | 2019-06-30 | 96.14% | −0.16 pp |
| Q1 2019 | 2019-03-31 | 95.69% | −0.69 pp |
| Q4 2018 | 2018-12-31 | 96.39% | +1.08 pp |
| Q3 2018 | 2018-09-30 | 95.92% | +1.20 pp |
| Q2 2018 | 2018-06-30 | 96.30% | +1.39 pp |
| Q1 2018 | 2018-03-31 | 96.38% | +1.50 pp |
| Q4 2017 | 2017-12-31 | 95.30% | +1.35 pp |
| Q3 2017 | 2017-09-30 | 94.71% | +0.75 pp |
| Q2 2017 | 2017-06-30 | 94.91% | +0.24 pp |
| Q1 2017 | 2017-03-31 | 94.88% | −0.52 pp |
| Q4 2016 | 2016-12-31 | 93.95% | +0.35 pp |
| Q3 2016 | 2016-09-30 | 93.97% | −0.32 pp |
| Q2 2016 | 2016-06-30 | 94.67% | −0.39 pp |
| Q1 2016 | 2016-03-31 | 95.40% | +1.03 pp |
| Q4 2015 | 2015-12-31 | 93.60% | +0.91 pp |
| Q3 2015 | 2015-09-30 | 94.29% | +0.11 pp |
| Q2 2015 | 2015-06-30 | 95.06% | +0.66 pp |
| Q1 2015 | 2015-03-31 | 94.37% | −0.19 pp |
| Q4 2014 | 2014-12-31 | 92.69% | — |
| Q3 2014 | 2014-09-30 | 94.18% | −3.20 pp |
| Q2 2014 | 2014-06-30 | 94.40% | −4.17 pp |
| Q1 2014 | 2014-03-31 | 94.56% | — |
| Q3 2013 | 2013-09-30 | 97.37% | — |
| Q2 2013 | 2013-06-30 | 98.58% | — |
Supernus Pharmaceuticals gross margin trends
Over the last five fiscal years, Supernus Pharmaceuticals's gross margin decreased from 89.92% to 89.63%, a change of −0.29 percentage points. The latest reported quarter, Q2 2026, shows 84.63%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
